Previous 10 | Next 10 |
SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 21, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is inve...
2023-05-19 14:59:05 ET Summary Sparsentan, a key competitor, falters in the Phase 3 DUPLEX study for FSGS, opening potential market opportunities for Chinook's atrasentan. Atrasentan's trial design in ALIGN may increase its chances of success compared to sparsentan. Chinook ha...
2023-05-17 09:28:09 ET Regarding safety, Divan pointed to the safety database from the earlier SONAR trial, as well as indications that atrasentan has better liver safety than Filspari. For further details see: Chinook defended at Guggenheim following short report
SAN FRANCISCO, May 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com ...
2023-05-16 12:39:57 ET Editor's note: Jonathan Block, the author of this article, has no relation to Muddy Waters founder Carson Block. For further details see: Chinook Therapeutics down 5% following Muddy Waters short report
BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Chinook Therapeutics, Inc. (NASDAQ: KDNY) for potential securities law violations. Investors who have lost money in their Chinook Therapeutics, Inc. investment should contact the firm to learn more about how they mi...
2023-05-16 11:49:50 ET Chinook Therapeutics ( NASDAQ: KDNY ) stock fell ~6% on Tuesday after the company said it is collaborating with Ionis Pharmaceuticals ( NASDAQ: IONS ) to discover, develop and sell an antisense oligonucleotide (ASO) therapy for a rare, severe chr...
SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chron...
2023-05-09 18:05:33 ET Chinook Therapeutics press release ( NASDAQ: KDNY ): Q1 GAAP EPS of -$0.85. Revenue of $1.8M (-33.3% Y/Y). Cash, cash equivalents and marketable securities totaled $357.4 million at March 31, 2023, compared to $385.3 million at December 31, 2022....
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...